# Daiichi Sankyo

递送平台 — 载体工程化.

Source: https://cn.bioecon.ru/companies/daiichi-sankyo/
Updated: 2026-07-02

- 国家: Japan

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 营收 | 2025财年为2,123.0 billion日元 | https://www.daiichisankyo.com/about_us/, https://www.daiichisankyo.com/files/investors/library/materials/2025/202601_JPM%20Conference_slide.pdf, https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Reference_Data_E.pdf |
| 员工人数 | 全球20,171名员工（截至2026年3月31日） | https://www.daiichisankyo.com/about_us/, https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/VR2024/1.%20About%20Daiichi%20Sankyo.pdf |
| 生产基地 | 全球13个生产基地 | https://www.daiichisankyo.com/about_us/, https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/VR2024/1.%20About%20Daiichi%20Sankyo.pdf |
| 融资 | 截至 2026 年初，已承诺投入约 3000亿日元（19亿美元）用于全球 ADC 产能扩建 | https://www.fiercepharma.com/manufacturing/daiichi-sankyo-tallies-19b-enhertu-manufacturing-investments-across-globe-report, https://www.pharmamanufacturing.com/facilities/article/55341804/daiichi-sankyo-invests-19b-to-boost-adc-production-globally |
| 产能 | 生物制品生产平台采用CHO细胞基因表达系统,产率高达10克/升 [中等置信度] | https://www.daiichisankyo.com/files/investors/library/materials/2023/DS%20seminar%202023_E.pdf |

独立来源: fiercepharma.com, pharmamanufacturing.com

## 技术

- [抗体偶联药物（ADC）](https://cn.bioecon.ru/technology/antibody-drug-conjugates-adcs/)